<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04775238</url>
  </required_header>
  <id_info>
    <org_study_id>Soh-Med-21-02-21</org_study_id>
    <nct_id>NCT04775238</nct_id>
  </id_info>
  <brief_title>Effect of Metallic Nanoparticles on Nosocomial Bacteria</brief_title>
  <official_title>Metallic Nanoparticles: Evaluation of Their Antibacterial, Antibiofilm and Synergistic Effect in Combination With Antibiotics on Nosocomial Bacteria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sohag University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sohag University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research aims to study the properties of metallic nanoparticles&quot;MNPs&quot; (silver&#xD;
      nanoparticles &quot;AgNps&quot; and copper nanoparticles &quot;CuNps&quot;) on the 2 most common nosocomial&#xD;
      bacteria which are highly resistant to antibiotics including Staphylococcus aureus and&#xD;
      Pseudomonas aeruginosa, to evaluate the growth inhibiting properties of MNPs on all bacterial&#xD;
      isolates, to evaluate the biofilm inhibitory effect on biofilm forming bacterial isolates and&#xD;
      the synergistic effect of these MNPs in combination with antibiotics on the antibiotic&#xD;
      resistant isolates.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is a rapid increase in the number of health care associated infections (HAIs) due to&#xD;
      multi-drug resistant (MDR) bacterial strains which have a worse prognosis being associated&#xD;
      with significant morbidity and mortality, particularly in critically ill patients. The main&#xD;
      problem with MDR strains is their limited treatment options, posing a major challenge for&#xD;
      health care providers.The increasing utilization and immense studies of nanoparticles have&#xD;
      brought new perspectives towards new antimicrobial material that could hinder the MDR&#xD;
      bacteria pandemic currently faced. Particularly, metallic nanoparticles exhibit strong&#xD;
      biocidal properties on different bacterial species, including MDR bacteria. Another important&#xD;
      aspect of the antimicrobial properties of metallic nanoparticles is their potential to&#xD;
      eradicate or inhibit microbial biofilm formation, which is an important virulence factor in&#xD;
      many localized chronic infections.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 27, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 20, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of the inhibition zone diameter by (mm) around wells containing silver nanoparticles on nutrient agar containing 105 cfu/ml (colony forming unit/ml) Staphylococcus aureus</measure>
    <time_frame>24 hours</time_frame>
    <description>Well diffusion method</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of the inhibition zone diameter by (mm) around wells containing silver nanoparticles on nutrient agar containing 105 cfu/ml Pseudomonas</measure>
    <time_frame>24 hours</time_frame>
    <description>Well diffusion method</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of the inhibition zone diameter by (mm) around wells containing copper nanoparticles on nutrient agar containing 105 cfu/ml Staphylococcus aureus</measure>
    <time_frame>24 hours</time_frame>
    <description>disc diffusion method</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of the inhibition zone diameter by (mm) around wells containing copper nanoparticles on nutrient agar containing 105 cfu/ml Pseudomonas</measure>
    <time_frame>24 hours</time_frame>
    <description>disc diffusion method</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibiofilm Activity:12 μg/mL of AgNPs will be added to 107 CFU/mL of Staph aureus. using a microtiter plate reader at 595 nm, biofilm scores: nonbiofilm forming (-), weak (+), moderate (++), and strong (+++)</measure>
    <time_frame>24 hours</time_frame>
    <description>Modified Tissue Culture Plate method (TCP):by ELISA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibiofilm Activity:12 μg/mL of CuNPs will be added to 107 CFU/mL of Staph aureus. using a microtiter plate reader at 595 nm, biofilm scores: nonbiofilm forming (-), weak (+), moderate (++), and strong (+++)</measure>
    <time_frame>24 hours</time_frame>
    <description>Modified Tissue Culture Plate method (TCP):by ELISA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibiofilm Activity:12 μg/mL of AgNPs will be added to 107 CFU/mL of Pseudomonas. Using a microtiter plate reader at 595 nm, biofilm scores: nonbiofilm forming (-), weak (+), moderate (++), and strong (+++)</measure>
    <time_frame>24 hours</time_frame>
    <description>Modified Tissue Culture Plate method (TCP):by ELISA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibiofilm Activity:12 μg/mL of CuNPs will be added to 107 CFU/mL of Pseudomonas. Using a microtiter plate reader at 595 nm, biofilm scores: nonbiofilm forming (-), weak (+), moderate (++), and strong (+++)</measure>
    <time_frame>24 hours</time_frame>
    <description>Modified Tissue Culture Plate method (TCP):by ELISA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Synergism with antibiotics: cefoxitin, Tetracyclin, Ciprofloxacin, Rifampin, Linezolide impregnated with 42.5 μg/mL AgNPs will be placed on nutrient agar containing 105 cfu/ml of Staph aureus. Inhibition zones will be measured (mm).</measure>
    <time_frame>24 hours</time_frame>
    <description>disc diffusion method</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Synergism with antibiotics: cefoxitin, Tetracyclin, Ciprofloxacin, Rifampin, Linezolide impregnated with 85 μg/mL CuNPs will be placed on nutrient agar containing 105 cfu/ml of Staph aureus. Inhibition zones will be measured (mm).</measure>
    <time_frame>24 hours</time_frame>
    <description>disc diffusion method</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Synergism with antibiotics:piperacillin-tazobactam, Aztreonam, Imipenem, Colistin, Ciprofloxacin impregnated with 42.5 μg/mL AgNPs will be placed on nutrient agar containing 105 cfu/ml of Pseudomonas. Inhibition zones will be measured (mm).</measure>
    <time_frame>24 hours</time_frame>
    <description>disc diffusion method</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Synergism with antibiotics:piperacillin-tazobactam, Aztreonam, Imipenem, Colistin ,Gentamicin, Ciprofloxacin impregnated with 85 μg/mL CuNPs will be placed on nutrient agar containing 105 cfu/ml of Pseudomonas. Inhibition zones will be measured (mm).</measure>
    <time_frame>24 hours</time_frame>
    <description>disc diffusion method</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Nosocomial Infections</condition>
  <arm_group>
    <arm_group_label>Group 1 (Staphylococcus aureus)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Staphylococcus aureus is an example of gram positive bacteria which is a strong biofilm producer and highly resistant to antibiotics. Staphylococcus aureus will be exposed to silver nanoparticles and copper nanoparticles separately to study their antibacterial and biofilm inhibiting properties and their synergistic effect in combination with antibiotics.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 (Pseudomonas aeruginosa )</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pseudomonas aeruginosa is an example of gram negative bacteria which is a strong biofilm producer and highly resistant to antibiotics. Pseudomonas aeruginosa will be exposed to silver nanoparticles and copper nanoparticles separately to study their antibacterial and biofilm inhibiting properties and their synergistic effect in combination with antibiotics.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Silver nanoparticles</intervention_name>
    <description>AgNPs (19±5 nm)</description>
    <arm_group_label>Group 1 (Staphylococcus aureus)</arm_group_label>
    <arm_group_label>Group 2 (Pseudomonas aeruginosa )</arm_group_label>
    <other_name>AgNPs</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Copper nanoparticles</intervention_name>
    <description>CuNPs (150-350 nm)</description>
    <arm_group_label>Group 1 (Staphylococcus aureus)</arm_group_label>
    <arm_group_label>Group 2 (Pseudomonas aeruginosa )</arm_group_label>
    <other_name>CuNPs</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Urinary tract infections (UTI)&#xD;
&#xD;
          -  Surgical site infections (SSI)&#xD;
&#xD;
          -  Catheter related blood stream infection (CRBSI)&#xD;
&#xD;
          -  Infected burns&#xD;
&#xD;
          -  Chest infection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients less than 18 years.&#xD;
&#xD;
          -  Community acquired infections&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nahed Fathallah, lecturer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sohag University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nahed Fathallah, lecturer</last_name>
    <phone>01142283865</phone>
    <email>nanafahmy_783@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ekram Abdelrahman, lecturer</last_name>
    <phone>+201004691692</phone>
    <email>dr.ekram.ar@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faculty of medicine - sohag university</name>
      <address>
        <city>Sohag</city>
        <zip>82524</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hassan Elnoamany, Professor</last_name>
      <phone>+201002554984</phone>
      <email>hassan.noaman@med.sohag.edu.eg</email>
    </contact>
    <contact_backup>
      <last_name>Mona Fattouh, Professor</last_name>
      <phone>+201009222054</phone>
      <email>monarahman2002@yahoo.co.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Ekram Abdelrahman, lecturer</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 22, 2021</study_first_submitted>
  <study_first_submitted_qc>February 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2021</study_first_posted>
  <last_update_submitted>March 2, 2021</last_update_submitted>
  <last_update_submitted_qc>March 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sohag University</investigator_affiliation>
    <investigator_full_name>Nahed Fathallah Fahmy</investigator_full_name>
    <investigator_title>lecturer of medical microbiology &amp; immunology departement -faculty of medicine- sohag university</investigator_title>
  </responsible_party>
  <keyword>Staphylococcus aureus</keyword>
  <keyword>Pseudomonas</keyword>
  <keyword>silver nanoparticles</keyword>
  <keyword>copper nanoparticles</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cross Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Copper</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

